Nonclinical services for the development of interventional agents for infectious diseases
Ended Awarded Last action
- Contract number
- 75N93024F00002
- Awardee
-
Eurofins Discovery Services North America, LLC UEI HF4LCAU68M93
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $443,794
Award facts
- Contract value 37% obligated
-
- $443,794.46 Current, with exercised options
- $1,210,710.46 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- St Charles, MO, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$2,010 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $445,804 |
About this award
This delivery order, awarded May 1, 2018, provides nonclinical services for the development of interventional agents targeting infectious diseases through the National Institute of Allergy and Infectious Diseases (NIAID). Eurofins Discovery Services North America, LLC, a foreign-owned contract research organization headquartered in St. Charles, Missouri, was awarded this firm-fixed-price delivery order with a ceiling value of $1.21 million and an ultimate completion date of April 30, 2025. The contract carries no set-aside designation and represents work performed under the parent Nonclinical Services for Development of Interventional Agents master indefinite delivery/indefinite quantity (IDIQ) vehicle. Eurofins' service delivery encompasses preclinical research methodologies including receptor binding studies, toxicology testing, and analytical chemistry—capabilities that align with NIAID's mission to develop medical countermeasures and therapeutic interventions for infectious disease threats.
The award reflects Eurofins' established expertise and trusted partnership with NIAID for specialized nonclinical research support. The company maintains significant federal contract experience across multiple agencies and currently holds four IDV contracts with combined ceiling values exceeding $84.9 million, including a substantial $50 million single-award contract with NIAID for interventional agents safety and pharmacokinetic services. Through this delivery order and related NIAID agreements, Eurofins continues to provide critical preclinical development services that support the government's research pipeline for infectious disease interventions, demonstrating the specialized and non-competitive nature of the contracted scientific capabilities required.
Quick answers
Who was awarded contract 75N93024F00002?
75N93024F00002 was awarded to Eurofins Discovery Services North America, LLC by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on May 1, 2018.
How much is contract 75N93024F00002 worth?
The government has obligated $443,794 on 75N93024F00002. Its potential value, with all options, is $1,210,710.
Is contract 75N93024F00002 an order under another contract?
Yes. 75N93024F00002 is a delivery order under 75N93018D00007, an indefinite delivery contract, on Nonclinical Services for Development of Interventional Agents.
Was contract 75N93024F00002 competed?
The extent of competition for 75N93024F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award